Want to know what healthcare stocks to buy? See what Edward Owens is buying. Over the past 10 years, his fund beats the benchmark by more than 8% per year. This his buys and sells during the fourth quarter of 2007.
Edward Owens buys Sepracor Inc., PDL BioPharma Inc., sells Aetna Inc. during the 3-months ended 12/31/2007, according to the most recent filings of his investment company, Vanguard Health Care Fund. Edward Owens owns 79 stocks with a total value of $24 billion. These are the details of the buys and sells.
New Purchases: PDLI, SEPR,
Added Positions: AMLN, MRK, NVO, UNH, WAG,
Reduced Positions: AXCA,
Sold Out: AET,
Added: Walgreen Company (WAG, Financial)
Edward Owens added to his holdings in Walgreen Company by 26.9%. The impact to his portfolio due to this purchase was 0.36%. His holdings were 10,850,000 shares as of 12/31/2007.
Walgreen Co. operates a chain of drugstores in the United States. These drugstores sell prescription and non-prescription drugs, and general merchandise. Walgreen Company has a market cap of $34.44 billion; its shares were traded at around $34.52 with a P/E ratio of 16.86 and P/S ratio of 0.62. The dividend yield of Walgreen Company stocks is 1.1%.
Added: Merck & Co. Inc. (MRK, Financial)
Edward Owens added to his holdings in Merck & Co. Inc. by 13.97%. The impact to his portfolio due to this purchase was 0.29%. His holdings were 9,791,200 shares as of 12/31/2007.
Merck & Co., Inc. engages in the discovery, development, manufacture, and marketing of products for human and animal health. It offers Singulair for treating asthma, and relief of symptoms of allergic rhinitis; Cozaar/Hyzaar etc. Merck & Co. Inc. has a market cap of $99.52 billion; its shares were traded at around $45.71 with a P/E ratio of 30.59 and P/S ratio of 4.11. The dividend yield of Merck & Co. Inc. stocks is 3.2%.
Added: Amylin Pharmaceuticals Inc. (AMLN, Financial)
Edward Owens added to his holdings in Amylin Pharmaceuticals Inc. by 414.3%. The impact to his portfolio due to this purchase was 0.25%. His holdings were 2,057,200 shares as of 12/31/2007.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. Amylin Pharmaceuticals Inc. has a market cap of $4.11 billion; its shares were traded at around $30.5 with P/S ratio of 5.27.
Added: NovoNordisk A/S (NVO, Financial)
Edward Owens added to his holdings in NovoNordisk A/S by 100%. The impact to his portfolio due to this purchase was 0.19%. His holdings were 1,400,000 shares as of 12/31/2007.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals. NovoNordisk A/S has a market cap of $37.89 billion; its shares were traded at around $60.35 with a P/E ratio of 23.09 and P/S ratio of 4.58. The dividend yield of NovoNordisk A/S stocks is 1%.
Added: UnitedHealth Group Inc. (UNH, Financial)
Edward Owens added to his holdings in UnitedHealth Group Inc. by 7.02%. The impact to his portfolio due to this purchase was 0.1%. His holdings were 6,100,000 shares as of 12/31/2007.
UnitedHealth Group Incorporated provides healthcare services in the United States. Its Uniprise segment delivers health care and well-being services to employers, individual consumers, and other health care organizations; and provides consumer-driven healthcare. UnitedHealth Group Inc. has a market cap of $62.76 billion; its shares were traded at around $49.38 with a P/E ratio of 14.34 and P/S ratio of 0.84. The dividend yield of UnitedHealth Group Inc. stocks is 0.1%.
New Purchase: Sepracor Inc. (SEPR, Financial)
Edward Owens initiated holdings in Sepracor Inc.. The impact to his portfolio due to this purchase was 0.45%. His holdings were 4,175,400 shares as of 12/31/2007.
Sepracor, Inc. engages in the research, discovery, development, and commercialization of pharmaceutical products for the treatment of respiratory and central nervous system disorders in the United States and Canada. Sepracor Inc. has a market cap of $2.89 billion; its shares were traded at around $27.39 with a P/E ratio of 17.65 and P/S ratio of 2.45.
New Purchase: PDL BioPharma Inc. (PDLI, Financial)
Edward Owens initiated holdings in PDL BioPharma Inc.. The impact to his portfolio due to this purchase was 0.05%. His holdings were 630,500 shares as of 12/31/2007.
PDL BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for severe or life-threatening illnesses. PDL BioPharma Inc. has a market cap of $1.71 billion; its shares were traded at around $13.89 with P/S ratio of 3.51.
Reduced: Axcan Pharma Inc. (AXCA, Financial)
Edward Owens reduced to his holdings in Axcan Pharma Inc. by 34.42%. The impact to his portfolio due to this sale was 0.05%. Edward Owens still held 704,900 shares as of 12/31/2007.
Axcan Pharma, Inc. engages in the research, development, manufacture, and distribution of pharmaceutical products for the treatment of gastrointestinal diseases and disorders primarily in North America and Europe. Axcan Pharma Inc. has a market cap of $1.26 billion; its shares were traded at around $22.76 with a P/E ratio of 16.39 and P/S ratio of 3.47.
Sold Out: Aetna Inc. (AET, Financial)
Edward Owens sold out his holdings in Aetna Inc.. The impact to his portfolio due to this sale was less than 0.01%.
Aetna, Inc. provides health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life, long-term care and disability plans, and medical management capabilities primarily in the United States. Aetna Inc. has a market cap of $26 billion; its shares were traded at around $53.28 with a P/E ratio of 15.26 and P/S ratio of 0.99. The dividend yield of Aetna Inc. stocks is 0.1%.
Edward Owens buys Sepracor Inc., PDL BioPharma Inc., sells Aetna Inc. during the 3-months ended 12/31/2007, according to the most recent filings of his investment company, Vanguard Health Care Fund. Edward Owens owns 79 stocks with a total value of $24 billion. These are the details of the buys and sells.
New Purchases: PDLI, SEPR,
Added Positions: AMLN, MRK, NVO, UNH, WAG,
Reduced Positions: AXCA,
Sold Out: AET,
Added: Walgreen Company (WAG, Financial)
Edward Owens added to his holdings in Walgreen Company by 26.9%. The impact to his portfolio due to this purchase was 0.36%. His holdings were 10,850,000 shares as of 12/31/2007.
Walgreen Co. operates a chain of drugstores in the United States. These drugstores sell prescription and non-prescription drugs, and general merchandise. Walgreen Company has a market cap of $34.44 billion; its shares were traded at around $34.52 with a P/E ratio of 16.86 and P/S ratio of 0.62. The dividend yield of Walgreen Company stocks is 1.1%.
Added: Merck & Co. Inc. (MRK, Financial)
Edward Owens added to his holdings in Merck & Co. Inc. by 13.97%. The impact to his portfolio due to this purchase was 0.29%. His holdings were 9,791,200 shares as of 12/31/2007.
Merck & Co., Inc. engages in the discovery, development, manufacture, and marketing of products for human and animal health. It offers Singulair for treating asthma, and relief of symptoms of allergic rhinitis; Cozaar/Hyzaar etc. Merck & Co. Inc. has a market cap of $99.52 billion; its shares were traded at around $45.71 with a P/E ratio of 30.59 and P/S ratio of 4.11. The dividend yield of Merck & Co. Inc. stocks is 3.2%.
Added: Amylin Pharmaceuticals Inc. (AMLN, Financial)
Edward Owens added to his holdings in Amylin Pharmaceuticals Inc. by 414.3%. The impact to his portfolio due to this purchase was 0.25%. His holdings were 2,057,200 shares as of 12/31/2007.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. Amylin Pharmaceuticals Inc. has a market cap of $4.11 billion; its shares were traded at around $30.5 with P/S ratio of 5.27.
Added: NovoNordisk A/S (NVO, Financial)
Edward Owens added to his holdings in NovoNordisk A/S by 100%. The impact to his portfolio due to this purchase was 0.19%. His holdings were 1,400,000 shares as of 12/31/2007.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals. NovoNordisk A/S has a market cap of $37.89 billion; its shares were traded at around $60.35 with a P/E ratio of 23.09 and P/S ratio of 4.58. The dividend yield of NovoNordisk A/S stocks is 1%.
Added: UnitedHealth Group Inc. (UNH, Financial)
Edward Owens added to his holdings in UnitedHealth Group Inc. by 7.02%. The impact to his portfolio due to this purchase was 0.1%. His holdings were 6,100,000 shares as of 12/31/2007.
UnitedHealth Group Incorporated provides healthcare services in the United States. Its Uniprise segment delivers health care and well-being services to employers, individual consumers, and other health care organizations; and provides consumer-driven healthcare. UnitedHealth Group Inc. has a market cap of $62.76 billion; its shares were traded at around $49.38 with a P/E ratio of 14.34 and P/S ratio of 0.84. The dividend yield of UnitedHealth Group Inc. stocks is 0.1%.
New Purchase: Sepracor Inc. (SEPR, Financial)
Edward Owens initiated holdings in Sepracor Inc.. The impact to his portfolio due to this purchase was 0.45%. His holdings were 4,175,400 shares as of 12/31/2007.
Sepracor, Inc. engages in the research, discovery, development, and commercialization of pharmaceutical products for the treatment of respiratory and central nervous system disorders in the United States and Canada. Sepracor Inc. has a market cap of $2.89 billion; its shares were traded at around $27.39 with a P/E ratio of 17.65 and P/S ratio of 2.45.
New Purchase: PDL BioPharma Inc. (PDLI, Financial)
Edward Owens initiated holdings in PDL BioPharma Inc.. The impact to his portfolio due to this purchase was 0.05%. His holdings were 630,500 shares as of 12/31/2007.
PDL BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for severe or life-threatening illnesses. PDL BioPharma Inc. has a market cap of $1.71 billion; its shares were traded at around $13.89 with P/S ratio of 3.51.
Reduced: Axcan Pharma Inc. (AXCA, Financial)
Edward Owens reduced to his holdings in Axcan Pharma Inc. by 34.42%. The impact to his portfolio due to this sale was 0.05%. Edward Owens still held 704,900 shares as of 12/31/2007.
Axcan Pharma, Inc. engages in the research, development, manufacture, and distribution of pharmaceutical products for the treatment of gastrointestinal diseases and disorders primarily in North America and Europe. Axcan Pharma Inc. has a market cap of $1.26 billion; its shares were traded at around $22.76 with a P/E ratio of 16.39 and P/S ratio of 3.47.
Sold Out: Aetna Inc. (AET, Financial)
Edward Owens sold out his holdings in Aetna Inc.. The impact to his portfolio due to this sale was less than 0.01%.
Aetna, Inc. provides health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life, long-term care and disability plans, and medical management capabilities primarily in the United States. Aetna Inc. has a market cap of $26 billion; its shares were traded at around $53.28 with a P/E ratio of 15.26 and P/S ratio of 0.99. The dividend yield of Aetna Inc. stocks is 0.1%.
